Drug Approval | November 30, 2022
CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
The teams will assist the state health authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
Subscribe To Our Newsletter & Stay Updated
